29 June 2024
: Case report
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment
Flavia Sanmartin1ABCDEF*, Eugenia Magrini1ABCDEF, Emanuele Rando1CDEF, Paola Del Giacomo2AF, Alex Dusina2AF, Elena Matteini1B, Andrea Carbone1B, Giuseppe Puma1B, Gabriele Maria Leanza1B, Federico Frondizi1B, Idanna Innocenti3C, Giuseppe Maiuro2A, Flora Marzia Liotti2ABCDE, Rosaria Santangelo2CD, Luca Laurenti3AB, Antonella Cingolani2ABDEDOI: 10.12659/AJCR.941165
Am J Case Rep 2024; 25:e941165
Figure 2. The virological response is expressed with the cut off index (COI) on the Y axis. Significant values are reported in the tables, with COI value and cycle threshold (Ct) values. This figure shows the trend of the virological response during 3 different anti-SARS-CoV-2 therapeutic regimens to which our immunocompromised patient was subjected. In chronological order, the following were administered: a 5-day cycle of remdesivir twice in a 2-month period, a single administration of tixagevimab/cilgavimab, a cycle of combined therapy of remdesivir and nirmatrelvir/ritonavir (Paxlovid), and finally, a 10-day cycle of remdesivir and nirmatrelvir/ritonavir (Paxlovid). The graph shows significant reduction in viral load following a combined or prolonged regimen of remdesivir and nirmatrelvir/ritonavir.